Poster-Disease-modifying Therapy
October 25, 2021
Whole Brain, Cortical Grey Matter, and Thalamic Volume Changes during 3 to 5 Years of Ozanimod in Relapsing MS
Background: Ozanimod reduced whole brain volume (WBV), cortical grey matter volume (CGMV), and thalamic volume (TV) loss vs interferon...
Poster-Disease-modifying Therapy
October 25, 2021
Real-World Cost of Care, Treatment Completion and Site of Care Cost for Patients with Multiple Sclerosis Initiating Infused Disease-Modifying Therapies
Background: Expenditures for intravenous (IV) disease-modifying therapies (DMTs) for multiple sclerosis (MS) include costs beyond wholesale...
Poster-Disease-modifying Therapy
October 25, 2021
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...
Poster-Disease-modifying Therapy
October 25, 2021
Assessment of Composite Disability Accumulation of Ponesimod Relative to Teriflunomide in the Optimum Phase 3 Study
Background: In relapsing forms of Multiple Sclerosis, disability progression has been shown to be independent of relapses. A new concept in...
Poster-Disease-modifying Therapy
October 25, 2021
Generic Perceptions: Measuring Opinions of Patients with MS Toward Generic Disease Modifying Therapies (DMTs)
Background: In 2018, the MS world received its first true generic DMT, and more generics will become available over the next few years....
Poster-Disease-modifying Therapy
October 25, 2021
MS Fatigue: Treatment Effect of Ponesimod in RMS Patients with and without Disease Activity
Background: NEDA or No evidence of disease activity (relapses, MRI lesions and disease progression) is increasingly used as a meaningful...
Poster-Disease-modifying Therapy
October 25, 2021
Evobrutinib Efficacy Is Maintained over Two Years in an Open-Label Phase II Study Extension in Patients with Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Bruton’s tyrosine kinase inhibitor with dual mode of action, targeting B cells and...